Transcatheter heart valve interventions: Where are we? Where are we going?

Bernard D. Prendergast; Helmut Baumgartner; Victoria Delgado; Olivier Gérard; Michael Haude; Anders Himmelmann; Bernard Iung; Matthew Leafstedt; Jasmine Lennartz; Francesco Maisano; Elena Andreassi Marinelli; Thomas Modine; Markus Mueller; Simon R. Redwood; Olaf Rörick; Cherif Sahyoun; Erika Saillant; Lars Søndergaard; Martin Thoenes; Karen Thomitzek; Marion Tschernich; Alec Vahanian; Olaf Wendler; Evelyn Julia Zemke; Jeroen J. Bax

doi:10.1093/eurheartj/ehy668

Transcatheter heart valve interventions: Where are we? Where are we going?

Bernard D. Prendergast, Helmut Baumgartner, Victoria Delgado, Olivier Gérard, Michael Haude, Anders Himmelmann, Bernard Iung, Matthew Leafstedt, Jasmine Lennartz, Francesco Maisano, Elena Andreassi Marinelli, Thomas Modine, Markus Mueller, Simon R. Redwood, Olaf Rörick, Cherif Sahyoun, Erika Saillant, Lars Søndergaard, Martin Thoenes, Karen ThomitzekMarion Tschernich, Alec Vahanian, Olaf Wendler, Evelyn Julia Zemke, Jeroen J. Bax^*

^*Corresponding author for this work

Research output: Contribution to journal › Review › Research › peer-review

56 Citations (Scopus)

Abstract

Transcatheter heart valve interventions have transformed the outcomes of patients with valvular heart disease (VHD) who are unfavourable candidates for surgery. Technological advances have allowed extension of these interventions to younger or lower risk patients and those with other forms of VHD and may in the future permit earlier treatment of VHD in less symptomatic patients or those with moderate disease. The balance of risks and benefits is likely to differ between lower and higher risk patients, and more evidence is needed to evaluate the net benefit of transcatheter technology in these groups. As academic researchers, clinicians, industry, and patient stakeholders collaborate to research these broader indications for transcatheter valve interventions, it is essential to address (i) device durability and deliverability, (ii) specific anatomical needs (e.g. bicuspid aortic valves, aortic regurgitation, mitral and tricuspid valve disease), (iii) operator training, and (iv) the reinforced importance of the multidisciplinary Heart Team.

Original language	English
Journal	European Heart Journal
Volume	40
Issue number	5
Pages (from-to)	422-440
Number of pages	19
ISSN	0195-668X
DOIs	https://doi.org/10.1093/eurheartj/ehy668
Publication status	Published - 2019

Keywords

Aortic valve
Heart valve disease
Mitral valve
Transcatheter aortic valve replacement
Tricuspid valve

Access to Document

10.1093/eurheartj/ehy668

Cite this

Prendergast, B. D., Baumgartner, H., Delgado, V., Gérard, O., Haude, M., Himmelmann, A., Iung, B., Leafstedt, M., Lennartz, J., Maisano, F., Marinelli, E. A., Modine, T., Mueller, M., Redwood, S. R., Rörick, O., Sahyoun, C., Saillant, E., Søndergaard, L., Thoenes, M., ... Bax, J. J. (2019). Transcatheter heart valve interventions: Where are we? Where are we going? European Heart Journal, 40(5), 422-440. https://doi.org/10.1093/eurheartj/ehy668

Transcatheter heart valve interventions : Where are we? Where are we going? / Prendergast, Bernard D.; Baumgartner, Helmut; Delgado, Victoria; Gérard, Olivier; Haude, Michael; Himmelmann, Anders; Iung, Bernard; Leafstedt, Matthew; Lennartz, Jasmine; Maisano, Francesco; Marinelli, Elena Andreassi; Modine, Thomas; Mueller, Markus; Redwood, Simon R.; Rörick, Olaf; Sahyoun, Cherif; Saillant, Erika; Søndergaard, Lars; Thoenes, Martin; Thomitzek, Karen; Tschernich, Marion; Vahanian, Alec; Wendler, Olaf; Zemke, Evelyn Julia; Bax, Jeroen J.

In: European Heart Journal, Vol. 40, No. 5, 2019, p. 422-440.

Research output: Contribution to journal › Review › Research › peer-review

Prendergast, BD, Baumgartner, H, Delgado, V, Gérard, O, Haude, M, Himmelmann, A, Iung, B, Leafstedt, M, Lennartz, J, Maisano, F, Marinelli, EA, Modine, T, Mueller, M, Redwood, SR, Rörick, O, Sahyoun, C, Saillant, E, Søndergaard, L, Thoenes, M, Thomitzek, K, Tschernich, M, Vahanian, A, Wendler, O, Zemke, EJ & Bax, JJ 2019, 'Transcatheter heart valve interventions: Where are we? Where are we going?', European Heart Journal, vol. 40, no. 5, pp. 422-440. https://doi.org/10.1093/eurheartj/ehy668

Prendergast, Bernard D. ; Baumgartner, Helmut ; Delgado, Victoria ; Gérard, Olivier ; Haude, Michael ; Himmelmann, Anders ; Iung, Bernard ; Leafstedt, Matthew ; Lennartz, Jasmine ; Maisano, Francesco ; Marinelli, Elena Andreassi ; Modine, Thomas ; Mueller, Markus ; Redwood, Simon R. ; Rörick, Olaf ; Sahyoun, Cherif ; Saillant, Erika ; Søndergaard, Lars ; Thoenes, Martin ; Thomitzek, Karen ; Tschernich, Marion ; Vahanian, Alec ; Wendler, Olaf ; Zemke, Evelyn Julia ; Bax, Jeroen J. / Transcatheter heart valve interventions : Where are we? Where are we going?. In: European Heart Journal. 2019 ; Vol. 40, No. 5. pp. 422-440.

@article{dc808e75bb1e482c85e943cb199559c1,

title = "Transcatheter heart valve interventions: Where are we? Where are we going?",

abstract = "Transcatheter heart valve interventions have transformed the outcomes of patients with valvular heart disease (VHD) who are unfavourable candidates for surgery. Technological advances have allowed extension of these interventions to younger or lower risk patients and those with other forms of VHD and may in the future permit earlier treatment of VHD in less symptomatic patients or those with moderate disease. The balance of risks and benefits is likely to differ between lower and higher risk patients, and more evidence is needed to evaluate the net benefit of transcatheter technology in these groups. As academic researchers, clinicians, industry, and patient stakeholders collaborate to research these broader indications for transcatheter valve interventions, it is essential to address (i) device durability and deliverability, (ii) specific anatomical needs (e.g. bicuspid aortic valves, aortic regurgitation, mitral and tricuspid valve disease), (iii) operator training, and (iv) the reinforced importance of the multidisciplinary Heart Team.",

keywords = "Aortic valve, Heart valve disease, Mitral valve, Transcatheter aortic valve replacement, Tricuspid valve",

author = "Prendergast, {Bernard D.} and Helmut Baumgartner and Victoria Delgado and Olivier G{\'e}rard and Michael Haude and Anders Himmelmann and Bernard Iung and Matthew Leafstedt and Jasmine Lennartz and Francesco Maisano and Marinelli, {Elena Andreassi} and Thomas Modine and Markus Mueller and Redwood, {Simon R.} and Olaf R{\"o}rick and Cherif Sahyoun and Erika Saillant and Lars S{\o}ndergaard and Martin Thoenes and Karen Thomitzek and Marion Tschernich and Alec Vahanian and Olaf Wendler and Zemke, {Evelyn Julia} and Bax, {Jeroen J.}",

year = "2019",

doi = "10.1093/eurheartj/ehy668",

language = "English",

volume = "40",

pages = "422--440",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Transcatheter heart valve interventions

T2 - Where are we? Where are we going?

AU - Prendergast, Bernard D.

AU - Baumgartner, Helmut

AU - Delgado, Victoria

AU - Gérard, Olivier

AU - Haude, Michael

AU - Himmelmann, Anders

AU - Iung, Bernard

AU - Leafstedt, Matthew

AU - Lennartz, Jasmine

AU - Maisano, Francesco

AU - Marinelli, Elena Andreassi

AU - Modine, Thomas

AU - Mueller, Markus

AU - Redwood, Simon R.

AU - Rörick, Olaf

AU - Sahyoun, Cherif

AU - Saillant, Erika

AU - Søndergaard, Lars

AU - Thoenes, Martin

AU - Thomitzek, Karen

AU - Tschernich, Marion

AU - Vahanian, Alec

AU - Wendler, Olaf

AU - Zemke, Evelyn Julia

AU - Bax, Jeroen J.

PY - 2019

Y1 - 2019

N2 - Transcatheter heart valve interventions have transformed the outcomes of patients with valvular heart disease (VHD) who are unfavourable candidates for surgery. Technological advances have allowed extension of these interventions to younger or lower risk patients and those with other forms of VHD and may in the future permit earlier treatment of VHD in less symptomatic patients or those with moderate disease. The balance of risks and benefits is likely to differ between lower and higher risk patients, and more evidence is needed to evaluate the net benefit of transcatheter technology in these groups. As academic researchers, clinicians, industry, and patient stakeholders collaborate to research these broader indications for transcatheter valve interventions, it is essential to address (i) device durability and deliverability, (ii) specific anatomical needs (e.g. bicuspid aortic valves, aortic regurgitation, mitral and tricuspid valve disease), (iii) operator training, and (iv) the reinforced importance of the multidisciplinary Heart Team.

AB - Transcatheter heart valve interventions have transformed the outcomes of patients with valvular heart disease (VHD) who are unfavourable candidates for surgery. Technological advances have allowed extension of these interventions to younger or lower risk patients and those with other forms of VHD and may in the future permit earlier treatment of VHD in less symptomatic patients or those with moderate disease. The balance of risks and benefits is likely to differ between lower and higher risk patients, and more evidence is needed to evaluate the net benefit of transcatheter technology in these groups. As academic researchers, clinicians, industry, and patient stakeholders collaborate to research these broader indications for transcatheter valve interventions, it is essential to address (i) device durability and deliverability, (ii) specific anatomical needs (e.g. bicuspid aortic valves, aortic regurgitation, mitral and tricuspid valve disease), (iii) operator training, and (iv) the reinforced importance of the multidisciplinary Heart Team.

KW - Aortic valve

KW - Heart valve disease

KW - Mitral valve

KW - Transcatheter aortic valve replacement

KW - Tricuspid valve

U2 - 10.1093/eurheartj/ehy668

DO - 10.1093/eurheartj/ehy668

M3 - Review

C2 - 30608523

AN - SCOPUS:85061012691

VL - 40

SP - 422

EP - 440

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 5

ER -